Article Text

Download PDFPDF
Is targeted lung cancer screening an opportune time to address cardiovascular risk?
  1. Marie Fisk1,
  2. Charlotte E Bolton2
  1. 1 Respiratory Medicine & Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
  2. 2 Respiratory Medicine, NIHR Nottingham Biomedical Research Centre Respiratory Theme, University of Nottingham, Nottingham, UK
  1. Correspondence to Dr Marie Fisk, Respiratory Medicine & Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK; mf503{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Lung cancer and cardiovascular disease (CVD) are both leading causes of mortality and morbidity in the UK and worldwide.1 2 Every day in the UK, approximately 130 people learn that they have lung cancer, and nearly 100 die because of it.3 For CVD, the numbers are even greater; on average, 460 people die each day due to it.4 These are pause for thought statistics that are a call to action for evidence-based public health initiatives that make a difference.

In early 2019, NHS England rolled out its targeted screening programme for lung cancer with low-radiation dose CT. At an estimated cost of £70 million, 10 regional community lung health check projects are planned, starting in areas with greatest lung cancer death rates and targeting high-risk individuals.5 6 Central to this initiative was the Macmillan funded Manchester study, which targeted these hard to reach individuals in the community as opposed to established healthcare settings. Health economics analysis indicated this approach was cost-effective, with high rates of early-stage lung cancer detection, which were amenable to radical treatments.7 8 There is ongoing debate, however, about the relative merits of a national targeted lung cancer screening project, particularly in the setting of an already overstretched NHS.9 To this end, rigorous audit and governance of the programme are crucial.5 Interestingly, alongside lung cancer detection, several lung cancer screening studies have also shown their study cohorts are at high risk of CVD.10–12

In this issue of the journal, …

View Full Text


  • Contributors MF and CEB contributed equally to this work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Lung cancer
    Mamta Ruparel Samantha L Quaife Jennifer L Dickson Carolyn Horst Stephen Burke Magali Taylor Asia Ahmed Penny Shaw May-Jan Soo Arjun Nair Anand Devaraj Emma Louise O'Dowd Angshu Bhowmik Neal Navani Karen Sennett Stephen W Duffy David R Baldwin Reecha Sofat Riyaz S Patel Aroon Hingorani Sam M Janes